New Industry KPIs for Evaluating PHM & VBC IT Vendors Prioritize AI-Driven Insights, Workflow Automation, and Real-World Clinical Impact - Top 2025 Vendors Recognized for Effectiveness and Client Experience

Strategic Partnership: RoStrategic Partnership: Royal Biologics and Coldplasmatech Revolutionize Complex Wound Careyal Biologics and Coldplasmatech Revolutionize Complex Wound Care

Innovative Redesign Brings Smaller, Cost-Effective Unit with Advanced Diagnostics to Consumers

- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -

- The Company recently entered into a Clinical Trial Collaboration Agreement with Revance to study DMT410 for the treatment of axillary hyperhidrosis -

- The Company also has an issued patent in Japan covering their DMT410 program for the treatment of hyperhidrosis -

Initial feasibility study of its soluble, Ph neutral, fast acting granular or powder drug delivery system is complete

Test results support the next development step with Phase 1clinical trial expected to commence in April

Provides Summary of Expected 2025 Milestones

DOHC won Best Home Health Care Services and Best Nurse/Nurse Practitioner

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Familial Chylomicronemia Syndrome

PharmPix further positions itself as a leader in the pharmacy benefit management arena as they are proud to announce their expansion into the Medicare market with the launch of MedArk™, a transformative platform designed to meet the complex needs of Medicare Part D plans.

During American Heart Month, the leading podiatry group is highlighting how evaluations of health issues with the feet can provide early detection of cardiovascular issues.

Spring Lake Ranch Therapeutic Community launches 18MM Capital Campaign.

What Does This Mean for the Future of EO Sterilization?

Meet Black Book top rated IT vendors at the AHA Rural Healthcare Leadership Conference

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025

PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024

Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025

Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025

Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028

Date: March 31, 2025, 10:36 A.M. 

Location: Moderated Poster Theater 7

PROGNOSTIC IMPLICATIONS OF PLATELET FCɣRIIA DURING THE FIRST YEAR AFTER MYOCARDIAL INFARCTION

A comprehensive, cost-cutting bundle offers a streamlined digital workflow from guided implant placement to delivery of the final restoration.

With the addition of SBG injections, the West Palm Beach integrative health clinic offers a new option to individuals looking for relief from chronic pain, trauma disorder, and other ailments

- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function -

Education event for occupational and environmental medicine physicians will cover biomechanics, research and clinical indications for use of long-duration ultrasound treatment for soft-tissue injury healing.  

The closing of the business combination with PowerUp Acquisition Corp. creates Nasdaq-listed biopharmaceutical company dedicated to developing breakthrough innovations in FDA approved drugs, nutraceuticals, and supplements

Aspire has multiple product candidates in key areas of medical needs such as a fast-acting aspirin product for cardiology emergencies and pain management, a proprietary Viagra/Cialis combination product, various bi-hormonal drugs such as testosterone, estrogen, weight loss, anti-seizure, and thyroid drugs. Supplements such as pre-workout and melatonin are already being developed using Aspire's proprietary sublingual delivery system.

Aspire Biopharma Holdings, Inc. ("Aspire Biopharma") is scheduled to begin trading on Nasdaq on February 20, 2025 under the ticker symbol "ASBP".

CNY Fertility Founder & CEO Dr. Robert Kiltz Applauds President Trump's Directive to Protect IVF Access and Aggressively Reduce Out-of-Pocket and Health Plan Costs for Fertility Treatment

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions

Availability of first IIT proof-of-concept results potentially in H1 2025

Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan-Drug Designation by the FDA and the European Medicines Agency (EMA) for both SBS-IF and MVID

The global leader in dental imaging technologies will showcase the latest innovations added to its digital ecosystem - a suite of tools and software designed to connect the entire digital workflow from diagnosis to delivery.

RMAT and Fast Track Designation

New Investor Presentation on Growth Strategy and Expected Sportstech Acquisition

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu

Fraxion, a leading provider of procure-to-pay solutions, has partnered with ZAGENO, the biotechnology industry's largest AI-powered marketplace for lab supplies.

Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million

1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide

The new study highlights the effectiveness of an automated system in optimizing laboratory test utilization, ensuring medical necessity verification, and streamlining payment processing.

Double board-certified facial plastic surgeon in Newburgh breaks down the closed rhinoplasty process.

VIA360™ Surgical System with proprietary ActiveInject™ Technology delivers viscoelas­tic where you want it, when you want it, giving surgeons unmatched precision and control.

Desert Oasis Healthcare has once again earned a spot on the prestigious Fortune Best Workplaces list

Acquisition grows Company's presence in New Jersey

AI, Automation & Human Agents Working Together to Drive Measurable Revenue Cycle Outcomes

Find out if Puravive is legit or not in WireDaily's latest and updated guide on Puravive reviews 2025 to help consumers make better-informed decisions.